Levodopa/Carbidopa/Entacapone Lannacher 200 mg/50 mg/200 mg filmomhulde tabletten

Land: Holland

Tungumál: hollenska

Heimild: CBG-MEB (College ter Beoordeling van Geneesmiddelen)

Kauptu það núna

Download Vara einkenni (SPC)
26-07-2023

Virkt innihaldsefni:

CARBIDOPA 1-WATER 54 mg/stuk SAMENSTELLING overeenkomend met ; CARBIDOPA 0-WATER 50 mg/stuk ; ENTACAPONE 200 mg/stuk ; LEVODOPA 200 mg/stuk

Fáanlegur frá:

Lannacher Heilmittel GmbH Schlossplatz 1 A-8502 LANNACH (OOSTENRIJK)

ATC númer:

N04BA03

INN (Alþjóðlegt nafn):

CARBIDOPA 1-WATER 54 mg/stuk SAMENSTELLING overeenkomend met ; CARBIDOPA 0-WATER 50 mg/stuk ; ENTACAPONE 200 mg/stuk ; LEVODOPA 200 mg/stuk

Lyfjaform:

Filmomhulde tablet

Samsetning:

CELLULOSE, MICROKRISTALLIJN (E 460(i)) ; CROSCARMELLOSE NATRIUM (E 468) ; GLYCEROL (E 422) ; HYPROLOSE (E 463) ; HYPROMELLOSE, Type 2910 (3 - 15 mPa.s) (E 464) ; IJZEROXIDE ROOD (E 172) ; LACTOSE 1-WATER ; MAGNESIUMSTEARAAT (E 470b) ; POLOXAMEER 188 ; POLYSORBAAT 80 (E 433) ; TITAANDIOXIDE (E 171), CELLULOSE, MICROKRISTALLIJN (E 460) ; CROSCARMELLOSE NATRIUM (E 468) ; GLYCEROL (E 422) ; HYPROLOSE (E 463) ; HYPROMELLOSE, Type 2910 (3 - 15 mPa.s) (E 464) ; IJZEROXIDE ROOD (E 172) ; LACTOSE 1-WATER ; MAGNESIUMSTEARAAT (E 470b) ; POLOXAMEER 188 ; POLYSORBAAT 80 (E 433) ; TITAANDIOXIDE (E 171),

Stjórnsýsluleið:

Oraal gebruik

Lækningarsvæði:

Levodopa, Decarboxylase Inhibitor And Comt Inhibitor

Vörulýsing:

Hulpstoffen: CELLULOSE, MICROKRISTALLIJN (E 460); CROSCARMELLOSE NATRIUM (E 468); GLYCEROL (E 422); HYPROLOSE (E 463); HYPROMELLOSE, Type 2910 (3 - 15 mPa.s) (E 464); IJZEROXIDE ROOD (E 172); LACTOSE 1-WATER; MAGNESIUMSTEARAAT (E 470b); POLOXAMEER 188; POLYSORBAAT 80 (E 433); TITAANDIOXIDE (E 171);

Leyfisdagur:

1900-01-01

Upplýsingar fylgiseðill

                                PACKAGE LEAFLET: INFORMATION FOR THE USER
LEVODOPA/CARBIDOPA/ENTACAPONE LANNACHER 50 MG/12,5 MG/200 MG
FILMOMHULDE TABLETTEN
LEVODOPA/CARBIDOPA/ENTACAPONE LANNACHER 75 MG/18,75 MG/200 MG
FILMOMHULDE TABLETTEN
LEVODOPA/CARBIDOPA/ENTACAPONE LANNACHER 100 MG/25MG/200 MG FILMOMHULDE
TABLETTEN
LEVODOPA/CARBIDOPA/ENTACAPONE LANNACHER 125 MG/31,25 MG/200 MG
FILMOMHULDE TABLETTEN
LEVODOPA/CARBIDOPA/ENTACAPONE LANNACHER 150 MG/37,5 MG/200 MG
FILMOMHULDE TABLETTEN
LEVODOPA/CARBIDOPA/ENTACAPONE LANNACHER 175 MG/43,75 MG/200 MG
FILMOMHULDE TABLETTEN
LEVODOPA/CARBIDOPA/ENTACAPONE LANNACHER 200 MG/50 MG/200 MG
FILMOMHULDE TABLETTEN
levodopa/carbidopa/entacapone
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm
them, even if their symptoms of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What Levodopa/Carbidopa/Entacapone Lannacher is and what it is used
for
2.
What you need to know before you take Levodopa/Carbidopa/Entacapone
Lannacher
3.
How to take Levodopa/Carbidopa/Entacapone Lannacher
4.
Possible side effects
5.
How to store Levodopa/Carbidopa/Entacapone Lannacher
6.
Contents of the pack and other information
1.
WHAT LEVODOPA/CARBIDOPA/ENTACAPONE LANNACHER IS AND WHAT IT IS USED
FOR
Levodopa/Carbidopa/Entacapone Lannacher contains three active
substances (levodopa,
carbidopa and entacapone) in one film-coated tablet.
Levodopa/Carbidopa/Entacapone Lannacher
is used for the treatment of Parkinson’s disease.
Parkinson’s disease is caused by low levels of a substance called
dopamine in the brain.
Levodopa increases the amount of dopamine and hence reduces the
symptoms of Parkinson
                                
                                Lestu allt skjalið
                                
                            

Vara einkenni

                                1.
NAME OF THE MEDICINAL PRODUCT
Levodopa/Carbidopa/Entacapone Lannacher 50 mg/12,5 mg/200 mg
filmomhulde tabletten
Levodopa/Carbidopa/Entacapone Lannacher 75 mg/18,75 mg/200 mg
filmomhulde tabletten
Levodopa/Carbidopa/Entacapone Lannacher 100 mg/25mg/200 mg filmomhulde
tabletten
Levodopa/Carbidopa/Entacapone Lannacher 125 mg/31,25 mg/200 mg
filmomhulde tabletten
Levodopa/Carbidopa/Entacapone Lannacher 150 mg/37,5 mg/200 mg
filmomhulde tabletten
Levodopa/Carbidopa/Entacapone Lannacher 175 mg/43,75 mg/200 mg
filmomhulde tabletten
Levodopa/Carbidopa/Entacapone Lannacher 200 mg/50 mg/200 mg
filmomhulde tabletten
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 50 mg of levodopa, 12.5 mg of
carbidopa anhydrous (as 13.5mg
Carbidopa monohydrate) and 200 mg of entacapone.
Each film-coated tablet contains 75 mg of levodopa, 18.75 mg of
carbidopa anhydrous (as 20.24
mg Carbidopa monohydrate) and 200 mg of entacapone.
Each film-coated tablet contains 100 mg of levodopa, 25 mg of
carbidopa anhydrous (as 27 mg
Carbidopa monohydrate) and 200 mg of entacapone.
Each film-coated tablet contains 125 mg of levodopa, 31.25 mg of
carbidopa anhydrous (as 33.74
mg Carbidopa monohydrate) and 200 mg of entacapone.
Each film-coated tablet contains 150 mg of levodopa, 37.5 mg of
carbidopa anhydrous (as 40.48
mg Carbidopa monohydrate) and 200 mg of entacapone.
Each film-coated tablet contains 175 mg of levodopa, 43.75 mg of
carbidopa anhydrous (as 47.23
mg Carbidopa monohydrate) and 200 mg of entacapone.
Each film-coated tablet contains 200 mg of levodopa, 50 mg of
carbidopa anhydrous (as 54 mg
Carbidopa monohydrate) and 200 mg of entacapone.
Excipient with known effect:
Each film-coated tablet of 50 mg levodopa/12.5 mg carbidopa
anhydrous/200 mg entacapone
contains 112 mg of lactose
Each film-coated tablet of 75 mg/levodopa/18.75 mg of carbidopa
anhydrous/200 mg entacapone
contains 124 mg of lactose .
Each film-coated tablet of 100 mg levodopa/25 mg of carbidopa
anhydrous/200 mg entacapone
contains 139 mg of la
                                
                                Lestu allt skjalið
                                
                            

Skjöl á öðrum tungumálum

Upplýsingar fylgiseðill Upplýsingar fylgiseðill enska 16-11-2016
Vara einkenni Vara einkenni enska 16-11-2016